R. de Paz Arias

Lessons learned for successful treatment of AML in the second wave of COVID-19 outbreak

V. Jiménez‐Yuste, A. Ramírez-López, I. Sánchez-Vadillo, 2021, Leukemia & lymphoma.

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

D. Faller, S. Kambhampati, L. Adès, 2021, Blood.

No transmission of SARS-CoV-2 in a patient undergoing allogeneic hematopoietic cell transplantation from a matched-related donor with unknown COVID-19

V. Jiménez Yuste, M. Canales Albendea, P. Lázaro Del Campo, 2020, Transfusion and Apheresis Science.

Nutritional intervention in oncohematological patient.

S. Palma Milla, C. Gómez-Candela, R. Burgos Peláez, 2012, Nutricion hospitalaria.

High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance

E. González-Barca, M. Ramírez, I. Jarque, 2019, Haematologica.

Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid

V. Jiménez Yuste, M. Canales Albendea, M. Gasior Kabat, 2020, Expert review of hematology.

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

C. Preudhomme, P. Fenaux, S. Thépot, 2022, Blood.

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

D. Faller, S. Kambhampati, L. Adès, 2022, Blood advances.